最近,上海市中药研究所与美国昆泰跨国有限公司正式签约,合作开展经美国FDA批准的“银杏灵”(中国注册名:杏灵颗粒)Ⅱ、Ⅲ期临床试验,这标志着银杏灵作为药品已开始被国际权威的药品管理部门接受,我国中药作为治疗药物已引起全球医药界的重视和关注,逐步为国际社会所接受。 Recently, the Shanghai Institute of Chinese Materia Medica officially signed a contract with U.S. Quintiles Transnational Co., Ltd. to jointly carry out phase II and III clinical trials of “Ginkgo biloba” (Chinese registered name: Xingling granules) approved by the US FDA, which indicates that Ginkgo Drugs have already begun to be accepted by internationally authoritative drug administration departments. As a therapeutic drug, Chinese medicine has attracted the attention and attention of the global medical community and has gradually been accepted by the international community.